Stockwinners Market Radar for May 02, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Francisco Partners, TPG to acquire Boomi from Dell Technologies - Francisco Partners and TPG Capital have entered into a definitive agreement with Dell Technologies to acquire Boomi, a leading provider of cloud-based integration platform as a service. The cash transaction is valued at $4B and is expected to close by the end of 2021, subject to customary closing conditions. Terms of the agreement were not disclosed.

17:39 EDT KKR announces completion of Natural Pet Food Group acquisition - Natural Pet Food Group and KKR announced the completion of KKR's acquisition of Natural Pet Food Group. The investment will be used to support the company's international growth and advance its mission to supply safe, sustainably sourced high-meat pet food from New Zealand to more customers and their pets worldwide. KKR will fund its investment from KKR Asian Fund IV. Additional details of the transaction are not disclosed.

10:29 EDT Li Auto delivered 5,539 Li ONEs in April 2021 - Li Auto announced that the company delivered 5,539 Li ONEs in April 2021, representing a 111.3% year-over-year increase and taking the cumulative deliveries to 51,715. "It took the company only 17 months to reach the milestone of the 50,000th delivery from the first delivery of Li ONE in December 2019, creating the fastest record among all new energy vehicle companies," Li Auto said. The company had 73 retail stores covering 53 cities, and 143 servicing centers and Li Auto-authorized body and paint shops operating in 105 cities as of April 30, 2021. Li Auto "expects to capture an increasing share of the electric vehicle market with existing and new model launches down the road and will further strengthen its direct sales and servicing network."

10:20 EDT Denali Therapeutics presents results from Phase 1/1b studies of BIIB122/DNL151 - Denali Therapeutics announced final results from Phase 1 and Phase 1b studies of its small molecule LRRK2 inhibitor, BIIB122/DNL151, which is being developed in collaboration with Biogen as a potential treatment of Parkinson's disease. Safety and biomarker goals were met in both studies, supporting plans to advance BIIB122/DNL151 into late-stage clinical development in Parkinson's disease by year-end 2021. Results from the Phase 1 study of healthy volunteers and the Phase 1b study of patients with Parkinson's disease showed achievement of robust target and pathway engagement with BIIB122/DNL151 treatment as measured by pS935 LRRK2 and pT73 Rab10, respectively. In addition, a dose-dependent reduction in urine of the lysosomal lipid BMP, a biomarker of lysosomal function, was achieved with BIIB122/DNL151 treatment, providing peripheral evidence supporting improvement of lysosomal function. BIIB122/DNL151 was generally well tolerated across a broad range of doses for up to 28 days, the longest treatment duration in both studies. Mutations in the LRRK2 gene can cause Parkinson's disease. LRRK2 is a regulator of lysosomal function, which is impaired in Parkinson's disease and may contribute to neurodegeneration. Inhibition of LRRK2 activity may slow the progression of Parkinson's disease in patients with and without known genetic risks based on restoration of lysosomal function.

10:06 EDT Unity Biotechnology presents UBX1325 data in diabetic retinopathy eye diseases - UNITY Biotechnology announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal vasculature and is differentiated from anti-VEGF agents in preclinical models. Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectively promotes apoptosis of diseased senescent cells of the retina, thereby restoring healthy vasculature and improving retinal function - important distinctions from anti-VEGF treatments. The research was presented in a poster presentation, "UBX1325, a small molecule inhibitor of Bcl-xL, attenuates vascular dysfunction in two animal models of retinopathy" during the Association for Research in Vision and Ophthalmology 2021 Annual Meeting. Bcl-xL is a molecular target that is highly expressed in diseased blood vessels during retinopathy, which have been shown to engage pathways of cellular senescence. In the study described, the novel senolytic candidate, UBX1325, selectively inhibits Bcl-xL, promoting apoptosis in oxygen induced retinopathy models but not normoxic controls. As demonstrated in models of retinopathy, vascular leakage and retinal function improved following a single injection of UBX1325 as measured by reduced retinal vascular permeability and improvements of retinal neovascularization and avascular area. Featured in an oral presentation at ARVO 2021, preclinical research of UBX1967, a selective Bcl-xL inhibitor that is molecularly distinct to UBX1325, demonstrated that the inhibition of Bcl-xL suppresses the formation of diseased blood vessels and targets Col1a1-positive endothelial cells that are associated with disease. The data included in the paper, "Inhibition of Bcl-xL with the small molecule UBX1967 targets Col1a1-positive endothelial cells in ischemic retinopathy" further supports the use of senolytic therapies to potentially target pathological vasculature without off-target effects on healthy blood vessels, as seen with anti-VEGF therapeutics.

10:00 EDT NIO delivered 7,102 vehicles in April 2021 - NIO provided its April 2021 delivery results. NIO said it delivered 7,102 vehicles in April 2021, representing a 125.1% year-over-year growth. The deliveries consisted of 1,523 ES8s, the company's six-seater and seven-seater flagship premium smart electric SUV, 3,163 ES6s, the company's five-seater high-performance premium smart electric SUV, and 2,416 EC6s, the company's five-seater premium smart electric coupe SUV. As of April 30, 2021, cumulative deliveries of the ES8, ES6 and EC6 reached 102,803 vehicles.